A-Cube
The profile is currenly unclaimed by the seller. All information is provided by CB Insights.
Stage
Acquired | AcquiredTotal Raised
$5MAbout A-Cube
Developer of technology to identify druggable sites on protein targets. The company utilizes in silico algorithms and bioinformatics (genomics and proteomics) to discover druggable targets suitable for developing human therapeutic interventions. The technology is used in various applications, including generating new IP against clinically validated targets; validating mAbs in an existing development portfolio; designing new vaccines; predicting epitopes on proteins; and determining a modified and less immunogenic structure of chronically administered proteins that induce neutralizing antibodies.
A-Cube Headquarter Location
530 Harbor Boulevard
Belmont, California, 94002,
United States
(650)610-9100
Expert Collections containing A-Cube
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
A-Cube is included in 1 Expert Collection, including Omics.
Omics
1,267 items
Companies involved in the capture, sequencing, and/or analysis of genomic, transcriptomic, proteomic, and/or metabolomic data
Where is A-Cube's headquarters?
A-Cube's headquarters is located at 530 Harbor Boulevard, Belmont.
What is A-Cube's latest funding round?
A-Cube's latest funding round is Acquired.
How much did A-Cube raise?
A-Cube raised a total of $5M.
Who are the investors of A-Cube?
Investors of A-Cube include Chartline Capital Partners and Japan Asia Investment.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.